BLFS: Coste Catherine reports shares returned to the company
By AlphaYouPublished Form 4
Coste Catherine
Reporting filer
Coste Catherine reports shares returned to the company, not an open-market purchase or sale, in Biolife Solutions Inc. Form 4 filed Oct 9, 2026 lists 1 entry.
- Disclosed
- Oct 9, 2026
Reported details
1 entry| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Coste Catherine | 2026-10-06 | D | Disposition to issuer | 13871 | Not stated (see footnotes) | 0 | 3 days | Filed terms
|
Common Stock
- Owner
- Coste Catherine
- Date
- 2026-10-06
- Code
- D
- Action
- Disposition to issuer
- Quantity
- 13871
- Price
- Not stated (see footnotes)
- Following holdings
- 0
- Reporting delay
- 3 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-10-06
- transaction Form Type: 4
- transaction Code: D
- equity Swap Involved: false
- transaction Shares: 13871
- id: F1
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 0
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Coste Catherine: Director.
- F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
Original sources
Prepared automatically from public filing data. Report a correction.